NCT00022893Unknown不适用
Retreatment Study of Patients With Non-Hodgkin's Lymphoma Who Have Previously Responded to Iodine-131 Anti-B1 Antibody.
适应症
相关药物
试验速览
- 阶段
- 不适用
- 试验地点
- 9
研究概览
简要总结
The purpose of this study is to enable retreatment with Iodine-131 Anti-B1 Antibody therapy for patients with non-Hodgkin's lymphoma (NHL) who previously responded (PR, CCR, or CR) for at least 3 months to Iodine-131 Anti-B1 Antibody therapy.
详细描述
The endpoints of the study are to determine the response rate, complete response rate, duration of response, time to progression, time-to-treatment failure, safety, and survival following Iodine-131 Anti-B1 Antibody therapy in patients with NHL who previously responded (PR, CCR, or CR) with a duration of response of at least 3 months to Iodine-131 Anti-B1 Antibody therapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have a histologically confirmed initial diagnosis of non-Hodgkin's B-cell lymphoma.
- •Patients must have previously responded (PR, CCR, or CR) with a duration of response of at least 3 months to Iodine-131 Anti-B1 Antibody therapy. The patient's disease must have progressed following the response to Iodine-131 Anti-B1 Antibody therapy.
- •Patients must have evidence that their tumor tissue expresses the CD20 antigen.
- •Patients must have a performance status of at least 60% on the Karnofsky Scale and an anticipated survival of at least 3 months.
- •Patients must have an absolute granulocyte count (ANC)>1,500 cells/mm3 (US) or >1,500 x 109/l (UK) and a platelet count >100,000 cells/mm3 (US) or >100,000 x 109/l (UK) within 14 days of study entry. These blood counts must be sustained without support of hematopoietic cytokines or transfusion of blood products.
- •Patients must have adequate renal function (defined as serum creatinine <1.5 x upper limit of normal) and hepatic function (defined as total bilirubin <1.5 x upper limit of normal and hepatic transaminases [AST and ALT] <5 x upper limit of normal) within 14 days of study entry.
- •Patients must have bi-dimensionally measurable disease. At least one lesion must be greater than or equal to 2 x 2 cm (by CT scan).
排除标准
- •Patients with more than an average of 25% of the intratrabecular marrow space involved by lymphoma in bone marrow biopsy specimens as assessed microscopically within 42 days of study entry. Bilateral posterior iliac crest core biopsies are required if the percentage of intratrabecular space involved exceeds 10% on a unilateral biopsy. The mean of bilateral biopsies must be no more than 25%.
- •Patients who have received cytotoxic chemotherapy, radiation therapy, immunosuppressants, or cytokine treatment within 4 weeks prior to study entry (6 weeks for nitrosourea compounds) or who exhibit persistent clinical evidence of toxicity. The use of systemic steroids must be discontinued at least 1 week prior to study entry.
- •Patients with active obstructive hydronephrosis.
- •Patients with evidence of active infection requiring IV antibiotics at the time of study entry.
- •Patients with New York Heart Association class III or IV heart disease or other serious illness that would preclude evaluation.
- •Patients with prior malignancy other than lymphoma, except for adequately treated skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease-free for 5 years. Patients who have been disease-free of another cancer for greater than 5 years must be carefully assessed at the time of study entry to rule out recurrent disease.
- •Patients with known HIV infection.
- •Patients with known brain or leptomeningeal metastases.
- •Patients who are pregnant or nursing (breastfeeding). Patients of childbearing potential must undergo a serum pregnancy test within 7 days prior to study entry. Males and females must agree to use effective contraception for 6 months following treatment.
- •Patients with previous allergic reactions to iodine. This does not include reacting to IV iodine-containing contrast materials.
- •Patients with progressive disease within 1 year of irradiation arising in a field that has been previously irradiated with >3500 cGy.
- •Patients who became HAMA positive following Iodine-131 Anti-B1 Antibody therapy or patients who are HAMA positive at the time of enrollment.
- •Patients who are concurrently receiving either approved or non-approved (through another protocol) anti-cancer drugs or biologics.
研究者
研究点 (9)
Loading locations...
相似试验
撤回
1 期
Assessing an Oral Bruton Tyrosine Kinase Inhibitor, DZD9008 in Patients Who Have Non-Hodgkin B-cell Lymphoma (WU-KONG3)Non-Hodgkin's B-cell LymphomaNCT04148742Dizal Pharmaceuticals120
已完成
2 期
Retreatment of Patients With Non-Hodgkin's Lymphoma Who Have Previously Responded to Iodine-131 Anti B1 AntibodyLymphoma, Non-HodgkinNCT00938041GlaxoSmithKline32
已完成
2 期
Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive HistologyLymphoma, Non-HodgkinNCT00950755GlaxoSmithKline41
招募中
不适用
Cellular Immunotherapy for Relapsed or Refractory Lymphoma Data CollectionLymphoma, Non-HodgkinNCT06541327Ruijin Hospital1,000
招募中
1 期
I-131MIBG therapy for the patients with newly diagnosed high-risk neuroblastomaneuroblastomaJPRN-jRCT2041190104Inaki Anri6